NCT01754389View on ClinicalTrials.gov

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

November 30, 2016

Conditions
Graft Versus Host Disease
Interventions
DRUG

Tacrolimus

DRUG

Methotrexate

DRUG

Bortezomib

DRUG

Sirolimus

Trial Locations (4)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Insitute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01754389 - Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant | Biotech Hunter | Biotech Hunter